FibroGen, AstraZeneca Up After Roxadustat Data
November 08 2019 - 3:19PM
Dow Jones News
By Michael Dabaie
AstraZeneca PLC (AZN) and FibroGen Inc. (FGEN) said roxadustat
Phase III program pooled analyses showed positive efficacy and no
increased cardiovascular risk in patients with anemia from chronic
kidney disease.
FibroGen shares turned positive after trading down earlier in
the session, recently up 9.5%, to $41.56. AstraZeneca ADRs also
turned positive, recently up 0.6%, at $47.09.
In non dialysis-dependent patients receiving roxadustat, the
risk of major adverse CV events, defined as all-cause mortality,
stroke and myocardial infarction, MACE+, which is defined as MACE,
unstable angina requiring hospitalization and congestive heart
failure requiring hospitalization, and all-cause mortality was
comparable to placebo, the companies said.
In incident dialysis patients, roxadustat had a lower risk of
MACE and MACE+ and showed a trend towards lower risk of all-cause
mortality relative to epoetin alfa.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 08, 2019 15:04 ET (20:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
